1. Home
  2. RYTM vs BCC Comparison

RYTM vs BCC Comparison

Compare RYTM & BCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • BCC
  • Stock Information
  • Founded
  • RYTM 2008
  • BCC 2004
  • Country
  • RYTM United States
  • BCC United States
  • Employees
  • RYTM N/A
  • BCC N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • BCC RETAIL: Building Materials
  • Sector
  • RYTM Health Care
  • BCC Consumer Discretionary
  • Exchange
  • RYTM Nasdaq
  • BCC Nasdaq
  • Market Cap
  • RYTM 4.3B
  • BCC 3.2B
  • IPO Year
  • RYTM 2017
  • BCC 2013
  • Fundamental
  • Price
  • RYTM $65.25
  • BCC $93.50
  • Analyst Decision
  • RYTM Strong Buy
  • BCC Buy
  • Analyst Count
  • RYTM 12
  • BCC 7
  • Target Price
  • RYTM $77.50
  • BCC $125.00
  • AVG Volume (30 Days)
  • RYTM 560.2K
  • BCC 321.7K
  • Earning Date
  • RYTM 08-05-2025
  • BCC 08-04-2025
  • Dividend Yield
  • RYTM N/A
  • BCC 6.73%
  • EPS Growth
  • RYTM N/A
  • BCC N/A
  • EPS
  • RYTM N/A
  • BCC 8.04
  • Revenue
  • RYTM $136,863,000.00
  • BCC $6,615,368,000.00
  • Revenue This Year
  • RYTM $37.56
  • BCC N/A
  • Revenue Next Year
  • RYTM $74.99
  • BCC $4.61
  • P/E Ratio
  • RYTM N/A
  • BCC $10.80
  • Revenue Growth
  • RYTM 48.88
  • BCC N/A
  • 52 Week Low
  • RYTM $40.46
  • BCC $83.60
  • 52 Week High
  • RYTM $69.89
  • BCC $155.42
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 53.08
  • BCC 47.27
  • Support Level
  • RYTM $60.80
  • BCC $86.96
  • Resistance Level
  • RYTM $64.00
  • BCC $89.40
  • Average True Range (ATR)
  • RYTM 1.96
  • BCC 1.99
  • MACD
  • RYTM -0.13
  • BCC 0.27
  • Stochastic Oscillator
  • RYTM 44.48
  • BCC 47.14

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About BCC Boise Cascade L.L.C.

Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two reportable segments, namely Wood Products and Building Materials Distribution. The Wood Products segment manufactures laminated veneer lumber (LVL), I-joists, and laminated beams. In addition, it manufactures structural, appearance, and industrial-grade plywood panels, and ponderosa pine lumber. The Building Materials Distribution segment is engaged in the distribution of various building materials, including oriented strand board (OSB), plywood, and lumber; general line items such as siding, composite decking, doors and millwork, metal products, roofing, and insulation; and EWP, among others. The company generates a majority of its revenue from the Building Material Distribution segment.

Share on Social Networks: